- Home
- FULC vs GSRT Comparison
FULC vs GSRT Comparison
Compare FULC & GSRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- GSRT
- Stock Information
- Founded
- FULC 2015
- GSRT 2023
- Country
- FULC United States
- GSRT United States
- Employees
- FULC N/A
- GSRT N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- GSRT
- Sector
- FULC Health Care
- GSRT
- Exchange
- FULC Nasdaq
- GSRT Nasdaq
- Market Cap
- FULC 372.2M
- GSRT 302.2M
- IPO Year
- FULC 2019
- GSRT 2024
- Fundamental
- Price
- FULC $6.40
- GSRT $10.38
- Analyst Decision
- FULC Buy
- GSRT Strong Buy
- Analyst Count
- FULC 8
- GSRT 1
- Target Price
- FULC $7.13
- GSRT $19.00
- AVG Volume (30 Days)
- FULC 420.8K
- GSRT 496.1K
- Earning Date
- FULC 07-29-2025
- GSRT 01-01-0001
- Dividend Yield
- FULC N/A
- GSRT N/A
- EPS Growth
- FULC N/A
- GSRT N/A
- EPS
- FULC N/A
- GSRT 0.19
- Revenue
- FULC N/A
- GSRT N/A
- Revenue This Year
- FULC N/A
- GSRT N/A
- Revenue Next Year
- FULC N/A
- GSRT N/A
- P/E Ratio
- FULC N/A
- GSRT $53.40
- Revenue Growth
- FULC 2752.05
- GSRT N/A
- 52 Week Low
- FULC $2.32
- GSRT $9.86
- 52 Week High
- FULC $9.30
- GSRT $11.49
- Technical
- Relative Strength Index (RSI)
- FULC 44.51
- GSRT 40.95
- Support Level
- FULC $6.36
- GSRT $10.35
- Resistance Level
- FULC $6.75
- GSRT $10.40
- Average True Range (ATR)
- FULC 0.30
- GSRT 0.05
- MACD
- FULC 0.01
- GSRT 0.01
- Stochastic Oscillator
- FULC 19.59
- GSRT 27.73
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About GSRT GSR III Acquisition Corp. Ordinary Shares
GSR III Acquisition Corp is a blank check company.